A sign stands in front of the Bristol-Myers Squib Company's headquarters in Lawrence Township in 2005. (AP Photo/Mel Evans)
A sign stands in front of the Bristol-Myers Squib Company’s headquarters in Lawrence Township in 2005. (AP Photo/Mel Evans)

(Reuters) – Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs.

The company said it will also discontinue its Hepatitis B and HIV early programs.

Bristol-Myers said already marketed products and its ongoing clinical programs in virology would not be hit by the decision.

The company is seeking U.S. approval for its experimental hepatitis C drug, daclatasvir.

READ MORE

Leave a comment

Your email address will not be published. Required fields are marked *

Yes, I would like to receive emails from Washington Informer Newspaper. Sign me up!


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, https://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact